U.S. Markets closed

How Much Are Bioanalytical Systems, Inc. (NASDAQ:BASI) Insiders Spending On Buying Shares?

Simply Wall St
·3 min read

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at whether insiders have been buying or selling shares in Bioanalytical Systems, Inc. (NASDAQ:BASI).

What Is Insider Buying?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, such insiders must disclose their trading activities, and not trade on inside information.

Insider transactions are not the most important thing when it comes to long-term investing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.

View our latest analysis for Bioanalytical Systems

The Last 12 Months Of Insider Transactions At Bioanalytical Systems

President Robert Leasure made the biggest insider purchase in the last 12 months. That single transaction was for US$100k worth of shares at a price of US$3.72 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$4.86. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

While Bioanalytical Systems insiders bought shares last year, they didn't sell. Their average price was about US$2.54. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqCM:BASI Recent Insider Trading, February 3rd 2020
NasdaqCM:BASI Recent Insider Trading, February 3rd 2020

Bioanalytical Systems is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 28% of Bioanalytical Systems shares, worth about US$15m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The Bioanalytical Systems Insider Transactions Indicate?

The fact that there have been no Bioanalytical Systems insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in Bioanalytical Systems and we see no evidence to suggest they are worried about the future. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow for free.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.